Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sysmex ( (JP:6869) ) has provided an update.
Sysmex will book an impairment loss of ¥11,557 million in the fourth quarter of the fiscal year ending March 31, 2026, mainly tied to goodwill at subsidiaries Sysmex Partec, Oxford Gene Technology IP, and Sysmex Astrego. The write-down follows impairment tests that reflected weaker cash flow projections and shifts in business environment and strategy, indicating that the recoverable value of these assets has fallen below their book value.
As a result of the impairment, Sysmex cut its full-year forecast for operating profit to ¥51 billion and profit attributable to owners of the parent to ¥35 billion, while keeping net sales unchanged at ¥500 billion. The downgrade marks a sharp earnings decline from both the previous forecast and fiscal 2025 results, though the company is maintaining its previously guided dividend, signaling a desire to reassure shareholders despite pressure on profitability.
The most recent analyst rating on (JP:6869) stock is a Hold with a Yen1500.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.
More about Sysmex
Sysmex Corporation, headquartered in Kobe, Japan, operates in the medical diagnostics and life sciences industry, focusing on hematology, clinical laboratory systems, and related testing technologies. The company expands its portfolio through specialized subsidiaries such as Sysmex Partec GmbH, Oxford Gene Technology IP Limited, and Sysmex Astrego AB, which support its position in advanced diagnostics and genomic solutions.
Average Trading Volume: 4,386,085
Technical Sentiment Signal: Sell
Current Market Cap: Yen870.6B
For an in-depth examination of 6869 stock, go to TipRanks’ Overview page.